Capivasertib
Sign in to save this workspacePrimary targets: AKT1, AKT2, AKT3 · FDA status: FDA Approved
Selectivity scorecard
KISS
96.48
Gini
0.644
CATDS
0.013
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Capivasertib. Strongest target: PKA at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PKA | 99.7% | 0.3% |
| 2 | P70S6K_RPS6KB1 | 98.9% | 1.1% |
| 3 | AKT3 | 98.5% | 1.5% |
| 4 | PRKX | 98.3% | 1.7% |
| 5 | PKACB | 97.8% | 2.2% |
| 6 | AKT1 | 97.7% | 2.3% |
| 7 | LATS2 | 96.2% | 3.8% |
| 8 | PKG1A | 96.0% | 4.0% |
| 9 | P70S6KB_RPS6KB2 | 95.7% | 4.3% |
| 10 | AKT2 | 95.3% | 4.7% |
| 11 | PKCG | 93.2% | 6.8% |
| 12 | MSK2_RPS6KA4 | 93.0% | 7.0% |
| 13 | MSK1_RPS6KA5 | 90.5% | 9.5% |
| 14 | PDGFRA | 90.3% | 9.7% |
| 15 | RSK1 | 88.8% | 11.2% |
| 16 | ROCK1 | 88.4% | 11.6% |
| 17 | LATS1 | 87.7% | 12.3% |
| 18 | ROCK2 | 85.6% | 14.4% |
| 19 | PKCD | 83.5% | 16.5% |
| 20 | PKN3_PRK3 | 82.2% | 17.8% |
Selectivity landscape
Where Capivasertib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Capivasertib.
Annotations
Sign in to read and post annotations.
Loading…